Skip to main content
OpenTrials
Completed

NCT Number: NCT01776216

Impact of Dairy Consumption on Hypertension: a Clinical Study

Hypertension and endothelial dysfunction are being increasingly recognized as key etiological factors in the development of atherosclerosis and subsequent cardiovascular disease (CVD). A substantial body of evidence indicates that treating patients with elevated blood pressure (BP) leads to marked reduction in the risk of stroke, myocardial infarction, heart failure, and renal failure. There is also accumulating evidence associating endothelial dysfunction, which is defined as incapacity of the arteries to vasodilate when required, to elevated BP and an increased risk of CVD.

While there are more and more studies on how diet affects BP in healthy subjects, the impact of dairy consumption per se on both endothelial function and ambulatory BP has not been well characterized in patients with established essential hypertension. Therefore, the general objective of the study is to investigate in a single-blind randomized controlled study the impact of dairy consumption on ambulatory BP and endothelial function in subjects with mild to moderate essential hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Institute of Nutraceuticals and Functional Foods (INAF)

Québec, Quebec, G1V 0A6, Canada

About this study

The proposed research will be undertaken as a single-center randomized cross-over controlled study. A total of 80 men and women with mild to moderate essential hypertension but otherwise healthy will consume two 4-week diets, one rich in dairy and one without dairy, while consuming a diet low in saturated fat (<10% energy), in trans fat (<1% energy) and in cholesterol (<200 mg/day). During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy (milk, yogurt, cheese) into their every day diet. During the CONTROL arm of the study, participants will be asked to consume energy equivalent replacement products. The primary analysis consists in comparing mean daytime ambulatory BP values and endothelial function between the two treatments.

A 2-week stabilization run-in period will precede the randomization of participants. During this run-in period, participants will be asked and instructed to adapt their diet to a prudent dietary pattern low in saturated fat (<10% energy), in trans fat (<1% energy) and in cholesterol (<200 mg/day). The total amount of fat in the diet will not be restricted, with recommendations ranging from 25-35% of energy. However, substitution of saturated for unsaturated fat will be advocated. Sodium intake <2300 mg/d will also be recommended. Recommendations will also include advice on how to restrict the consumption of processed and energy dense foods. This 2-week run-in period will allow participants to familiarize themselves with the dietary recommendations used during the intervention per se. The two diets will be separated by a 4-week wash out period and will also consist to the prudent dietary pattern recommended. It must be stressed that foods will not be provided during the run-in and wash-out periods. These periods are imposed to minimize the inter- and intra-individual variability before and between the experimental phases.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women aged between 18 and 70 years
  • Mean daytime systolic blood pressure ≥ 135 mm Hg and ≤ 160 mm Hg
  • Mean daytime diastolic blood pressure ≤ 110 mm Hg
  • Consumption of dairy products fewer than 2 servings per day

Exclusion criteria

  • Mean daytime systolic blood pressure > 160 mm Hg
  • Mean daytime diastolic blood pressure > 110 mm Hg
  • Dairy intake > 2 serving per day
  • Smokers (>1 cigarette/day)
  • Body weight variation >10% during the last 6 months prior to the study baseline
  • BMI >35 kg/m2
  • Previous history of cardiovascular disease, type 2 diabetes and monogenic dyslipidemia
  • Subject taking anti-inflammatory drugs
  • Subject with endocrine or gastrointestinal disorders
  • Allergy, intolerance or aversion to dairy
  • Clinical use of vitamin D or calcium supplements
  • Vegetarians

Treatment and study plan

Dairy diet

Other

During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy: 375 ml of reduced fat milk (1% fat), 175 g of low fat yogurt (1.5% fat) and 30g of regular cheese (34% fat) into their every day diet.

Other names: Dairy products, Milk, Yogourt, Cheese

Control diet

Other

During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products (290 ml of fruit juice, 156 ml of vegetable juice, 1 homemade cookie, 20g of cashew).

Primary outcomes

  1. Change in mean daytime systolic blood pressure

    Time frame: At the fisrt visit of the study (screening) and at the end of the two 4-weeks diets (week 4 and week 12)

    Mean daytime systolic blood pressure will be measured by 24-h ambulatory blood pressure monitoring using the Spacelabs 90207 (Spacelabs, Inc., Redmond, WA)

Secondary outcomes

  1. Change in mean daytime diastolic blood pressure

    Time frame: At the first visit of the study (screening) and at the end of the two 4-weeks diets (week 4 and week 12)

    Mean daytime diastolic blood pressure will be measured by 24-h ambulatory blood pressure monitoring using the Spacelabs 90207 (Spacelabs, Inc., Redmond, WA)

  2. Change in endothelial function

    Time frame: At the end of the two 4-weeks diets (week 4 and week 12)

    Digital pulse amplitude will be measured with a PAT device placed on the tip of each index finger (Endo-PAT2000, Itamar Medical, Caesarea, Israel)

Sponsors and collaborators

Lead sponsor

Laval University

Other

Collaborators

  • Dairy Farmers of Canada

Registry information

Official study title

Impact of Dairy Consumption on Hypertension: a Clinical Study.

Acronym: PLAT

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Jan 28, 2013
Registry last updated
Feb 7, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.